Obermeyer Wood Investment Counsel, Lllp Incyte Corp Transaction History

Obermeyer Wood Investment Counsel, Lllp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$63.34 - $74.11 $401,322 - $469,560	-6,336 Reduced 68.24%	2,949 $216,000
Q2 2021 Jul 29, 2021	SELL	$79.87 - $87.53 $85,301 - $93,482	-1,068 Reduced 10.32%	9,285 $781,000
Q1 2021 May 10, 2021	BUY	$76.02 - $100.5 $305,372 - $403,708	4,017 Added 63.4%	10,353 $841,000
Q1 2020 Apr 30, 2020	BUY	$63.18 - $85.97 $2,274 - $3,094	36 Added 0.57%	6,336 $464,000
Q4 2019 Feb 03, 2020	SELL	$73.04 - $95.72 $438 - $574	-6 Reduced 0.1%	6,300 $550,000
Q3 2019 Nov 06, 2019	BUY	$72.82 - $86.52 $436 - $519	6 Added 0.1%	6,306 $468,000
Q3 2017 Nov 02, 2017	BUY	$109.15 - $138.27 $687,645 - $871,101	6,300	6,300 $735,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Obermeyer Wood Investment Counsel, Lllp, based on Form 13F filings with the SEC.

Stay updated on Obermeyer Wood Investment Counsel, Lllp with notifications on news.